Transgenomic, a genetic analysis and services company, has entered into a agreement with the Guangzhou Family Planning Center in Guangzhou, China to set up a laboratory.
As part of the deal, Transgenomic will partner Guangzhou Laboratory to provide pharmacogenomic analyses within the Guangzhou Laboratory for pharmaceutical companies who choose to pursue clinical trials in China. The company has already equipped the facility with the instrument system technology needed to provide these sophisticated pharmacogenomics services.
Mr Craig Tuttle, President and CEO, Transgenomic said, under Chinese law, samples collected in China must be tested in China. The Guangzhou laboratory provides the facility to enable us to offer our pharmaceutical customers the testing capabilities they seek as they expand their clinical trial efforts to Asia, opening significant new clinical testing opportunities for us and strengthening our position as a leading supplier to our pharmaceutical partners in their worldwide efforts to bring new drugs to market.